Is China Pharma’s New Cash Cow Or A Policy Risk?

The pharmaceutical industry is engaging in a flurry of biotech deals and shifting clinical trials to China. It does so at a time when the U.S. is distancing from China.

Continue Reading

News Source: www.forbes.com